Accueil / Communiqués / Goldfinch Bio to Present at the Oppenheimer 29th Annual Healthcare Conference

Goldfinch Bio to Present at the Oppenheimer 29th Annual Healthcare Conference

Tuesday, March 12th 2019 at 1:00pm UTC

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Goldfinch Bio, a biotechnology company focused on discovering and
developing precision medicines for the treatment of genetically-driven
kidney diseases, today announced that Anthony Johnson, M.D., President
and Chief Executive Officer of Goldfinch Bio, will present at the
Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20,
2019 at 8:00 a.m. ET in New York.

About Goldfinch Bio
Goldfinch Bio is a biotechnology company
that is singularly focused on discovering and developing precision
therapies for patients with kidney diseases. Just as the goldfinch has
long been a symbol of healing and renewal and was a prominent figure of
the Renaissance, Goldfinch Bio is leading a new age of therapeutic
discovery to transform the treatment paradigm for patients with kidney
diseases. Goldfinch was launched in 2016 by Third Rock Ventures, and is
headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.

Contacts

The Yates Network
Gina Nugent 617-460-3579
gina@theyatesnetwork.com

Source: Goldfinch Bio


Voir aussi

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Thursday, March 21st 2019 at 4:45pm UTC Executed strategic agreement for Imeglimin with Roivant Sciences; …